Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...
Akums launches first-of-its-kind Lasmiditan dispersible tablets for rapid migraine care: Our Bureau, Mumbai Wednesday, March 18, 2026, 15:40 Hrs [IST] Akums Drugs & Pharmaceutical ...
TRIUMEQ PD is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in children. TRIUMEQ PD contains the prescription medicines Abacavir, ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...
Triumeq PD is the first dispersible single tablet regimen containing dolutegravir for children living with HIV The authorisation is an important step to meet ViiV Healthcare’s commitment to bring ...
A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...
Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...
* VIIV HEALTHCARE -TIVICAY PD, EXTENDED INDICATION OF EXISTING TIVICAY 50MG FILM-COATED TABLET ARE CURRENTLY UNDER REVIEW BY EUROPEAN MEDICINES AGENCY * VIIV HEALTHCARE - DOLUTEGRAVIR IS 1ST INTEGRASE ...
Approved by Swissmedic, sweet-tasting Coartem® Dispersible is an easy-to-administer medicine that promotes effective treatment for children with malaria Recent study published in The Lancet shows ...
GPs have been advised to avoid prescribing effervescent, dispersible and soluble formulations of drugs after a study found they were associated with significantly increased risk of heart attacks and ...
Fizzy drug formulations may pose CV risk Taking effervescent medication on a regular basis may increase patients' risk for cardiovascular events due to excess sodium. Effervescent, dispersible and ...
Deborah Waterhouse, CEO of ViiV Healthcare, said: “ I am delighted that our innovative approach to science has enabled us to achieve FDA approval of the first-ever dispersible tablet formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results